INTRODUCTION
It has been suggested that there are racial or ethnic differences with regard to the adverse event (AE) profile of moleculartargeting agents for cancer therapy. For example, interstitial lung disease caused by gefitinib or erlotinib, which are epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), is more frequent in Japanese than Caucasian lung cancer patients (1 -3) . Sunitinib, a multitargeting TKI for the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has been suggested to cause thrombocytopenia more frequently in Asians than Caucasians (4 -6). Moreover, a higher incidence of hand -foot syndrome and diarrhea has been reported in the Asia-Pacific region compared with Western countries during treatment with sorafenib, which is another multitargeting TKI for the VEGF and PDGF receptors (7, 8) .
The RECORD-1 study was a large-scale international Phase III trial that established the efficacy of everolimus, an inhibitor of mammalian target of rapamycin (mTOR), for advanced renal cell carcinoma (RCC) in patients with prior sunitinib and/or sorafenib treatment. However, this trial only included 24 Japanese patients, 15 of whom received everolimus while 9 received placebo (9 -11) . Therefore, the AE profile obtained from the RECORD-1 study may not accurately reflect that for a larger group of Japanese patients. Accordingly, the present study was performed to elucidate the AE profile of everolimus in Japanese patients with advanced RCC receiving realworld treatment. The time to treatment failure (TTF) was also investigated.
PATIENTS AND METHODS
We retrospectively investigated patients who had been treated with everolimus for unresectable or metastatic RCC at 39 Japanese medical centers between January 2010 and November 2011. Their baseline characteristics, the TTF and AEs classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) were reviewed based on the data from the case report forms for post-marketing surveillance that are required by the Japanese authorities. The protocol was approved by the Institutional Review Board in each participating institute. TTF was calculated from the start of treatment until its discontinuation for any reason. Kaplan -Meier curves were drawn for TTF, and the statistically significant differences in the TTF curves were determined using the log-rank test. The MannWhitney U test was used for analysis of the difference in the times to first occurrence of AEs. Fisher's exact test was used to analyze the difference in the reasons for discontinuation of everolimus between patients with and without dose modification after experiencing at least one AE. A level of P , 0.05 was accepted as statistical significance. Data were analyzed with Stat Flex ver.6 (Artech Co., Inc., Osaka, Japan).
RESULTS

PATIENT CHARACTERISTICS
A total of 180 patients were enrolled in this analysis, and their clinical characteristics at the start of everolimus therapy are shown in Table 1 . The median age was 65 years (range 23 -93 Fig. 1 . The reason for discontinuation of everolimus treatment was disease progression in 71 patients (54%), intolerable AEs in 47 patients (36%) and other reasons (including patient preference and transfer to another hospital) in 13 patients (10%). The median treatment period was 1.5 months (range 0.1-12.6 months) for patients who discontinued everolimus due to AEs, which was significantly shorter than the period of 3.2 months (range 0.1-16.6 months) for those who continued treatment until disease progression (P , 0.01, data not shown). Table 2 shows the major treatment-related AEs. A total of 89% of the patients experienced at least one AE during everolimus treatment and Grade 3 or 4 AEs occurred in 60% of them. Stomatitis was the most frequent AE, occurring in 44% of the patients, followed by thrombocytopenia (31%), anemia (22%), interstitial pneumonia (22%) and hyperglycemia (17%). Grade 3 interstitial pneumonia occurred in 6% of the patients. The cumulative incidence of the first occurrence of the five major AEs after the start of everolimus treatment is indicated in Fig. 2 . The median time to first occurrence of interstitial pneumonia (58.0 days) was significantly longer than that of stomatitis (12.0 days, P , 0.0001), thrombocytopenia (13.0 days, P , 0.0001), anemia (17.0 days, P , 0.001) or hyperglycemia (21.0 days, P , 0.001).
AE PROFILE
ASSOCIATION BETWEEN DOSE MODIFICATION AND TTF Table 3 shows the reasons for discontinuation of everolimus according to the dose modification status in patients who experienced at least one AE. The proportion of the patients who discontinued everolimus due to intolerability was significantly smaller in those who had modification in everolimus dose, including suspension or reduction of everolimus dose, than those who continued full dose of everolimus after AEs (23% versus 55%, P ¼ 0.0016). The median TTF was significantly longer in the group with dose modification (4.2 months; 95% CI: 3.4 -5.0) than in those without dose modification (1.7 months; 95% CI: 1.0 -2.3) after AEs among 160 patients who experienced at least one AE (P , 0.01, Fig. 3 ). Table 4 shows AEs that caused discontinuation of everolimus according to the dose modification status. Interstitial pneumonia was the most frequent cause of discontinuation in both the patient groups with and without dose modification. Among the 12 patients who discontinued everolimus due to AEs despite dose modification, the reasons for discontinuation were different from the reasons for dose modification in seven patients, whereas they were identical in the rest five patients. The AEs, which were overcome by dose modification for 
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Everolimus for advanced RCC those seven patients mentioned above, included thrombocytopenia for two patients, leukopenia and thrombocytopenia for two, stomatitis and fatigue for one, abnormal liver function tests for one and edema for one. The AEs which caused discontinuation, identical to those that caused dose modification in five patients mentioned above, included interstitial pneumonia for two patients, anorexia and vomiting for one, creatinine increase for one and hemorrhage for one.
DISCUSSION
Ethnic differences with regard to the clinical efficacy and toxicity of anticancer agents have been increasingly reported for patients with various cancers. In the case of breast cancer, a large-scale retrospective study of more than 5000 patients demonstrated more hot flushes, fatigue and arthritis in Caucasians than in black, Hispanic or Asian patients treated with hormonal therapy (12) . Grade 3 or 4 toxicity was more common in whites than in blacks receiving combination therapy with oxaliplatin, irinotecan and 5-fluorouracil (FU) for metastatic colorectal cancer according to a multicenter trial sponsored by the National Cancer Institute (13) . In addition, the frequency of diarrhea, nausea, vomiting and stomatitis was significantly lower in African-Americans than in Caucasians with Stage II or III colorectal cancer receiving 5-FU-based adjuvant chemotherapy (14) . A comparison of toxicity and the clinical response between Japanese and Caucasian lung cancer patients has been performed by common arm studies, and it was shown that Japanese patients with small-cell lung cancer had a significantly higher response rate than North American patients when treated with cisplatin and irinotecan or etoposide and cisplatin (15) . However, Japanese patients also experienced more Grade 3 or 4 leukopenia, neutropenia and anemia than North American patients (who were predominantly Caucasians) (15) . Another common arm study was performed using paclitaxel and carboplatin for advanced non-small-cell lung cancer, and it revealed that Japanese patients experienced more Grade 3 or 4 neutropenia, anemia and febrile neutropenia than Caucasians, while Japanese patients had a longer median survival time (16) .
Various molecular-targeting agents have recently been approved for the treatment of advanced RCC, but there have not been any studies in which racial differences between Japanese and Caucasians have been systematically analyzed with respect to toxicity and the response of RCC in patients receiving these agents. Based on the comparison of data from a Phase II study of sunitinib involving 25 treatment-naïve Japanese patients and data from a Western Phase III trial of first-line therapy, Japanese patients experience more Grade 3 or 4 thrombocytopenia (56 versus 9%) and neutropenia (44 versus 18%) than Western patients (17, 18) . Japanese patients also achieve longer median progression-free survival (12.2 versus 11 months) and overall survival (33.1 versus 26.4 months) than the Western patients.
The results of our present study indicate that there was a higher incidence of thrombocytopenia (31 versus 23%) and pneumonitis (22 versus 14%) due to everolimus in Japanese RCC patients compared with data from the RECORD-1 International Phase III trial (9, 10) . In contrast, anemia (22 versus 92%), hyperglycemia (17 versus 57%), hypercholesterolemia (13 versus 77%) and hypertriglyceridemia (13 versus 73%) were rather less frequent in Japanese patients than in the global patient population. The same tendency was seen in Grade 3 or higher AEs; thrombocytopenia (5 versus 1%) and pneumonitis (6 versus 4%) occurred more frequently, and anemia (9 versus 13%) and hyperglycemia (4 versus 15%) occurred less frequently in Japanese than in the global patient population. These results suggest that there may be some racial/ethnic differences in the AE profile of everolimus.
Such differences in treatment outcomes (AEs and response) may result from ethnic differences in the polymorphism of genes involved in metabolism of these drugs, leading to differences in enzyme activity. For example, it has been reported that polymorphism of CYP1A1, which is involved in the metabolism of TKIs, is associated with an increased risk of leukopenia and mucosal inflammation due to sunitinib therapy (19) . However, results of a Phase I clinical and pharmacokinetic study of everolimus in previously treated Japanese patients with advanced solid tumors demonstrated that its pharmacokinetics and tolerability were similar to those observed in previous studies that included large populations of Caucasian patients, for whom the most frequent drug-related toxicities included rash, stomatitis and fatigue (20) . No doselimiting toxicities were noted in that Phase I study.
Mutations of the drug targets in tumors may also contribute to ethnic differences. It has been reported that Asian patients have a significantly higher rate of somatic EGFR mutations than other populations, rendering their tumors more susceptible to treatment with EGFR-TKIs (2,21). It has also been reported that the presence of longer dinucleotide repeat segments in intron 1 of the EGFR gene results in lower EGFR expression, which is predicted to increase the response rate to EGFR-TKIs, and occurs more commonly in Asians than in Caucasians (21, 22) . So far, there has not been any report on somatic mTOR mutations, which explains ethnic differences in the toxicity, response rate and survival time of mTOR inhibitors.
The median TTF was only 2.9 months (95% CI: 2.4 -3.4 months) in the present study, which was markedly shorter compared with the median progression-free survival time of 4.9 months in the RECORD-1 trial (9). One of the reasons for this result may have been frequent early discontinuation of therapy due to AEs. The proportion of patients who discontinued everolimus due to AEs were statistically smaller in those who had modifications in the dose of everolimus than in those who had continued the full dose after experiencing at least one AE (23 versus 55%, Table 3 ). The median TTF was statistically longer in patients who had modifications in the dose of everolimus than in those who continued the full dose after experiencing at least one AE (4.2 months versus 1.7 months, 1136 Everolimus for advanced RCC Fig. 3 ). These results suggest that strategic management of AEs, including dose modification of everolimus may reduce discontinuation of the treatment due to intolerability, leading to longer treatment period. However, the current study was absolutely retrospective and the dose-modification status was itself one of the treatment results. Therefore, patients who had longer treatment periods might have more opportunity to be modified in everolimus dose. Table 4 revealed that none of the patients with dose modification of everolimus discontinued everolimus due to thrombocytopenia or leukopenia, suggesting that thrombocytopenia and leukopenia may be overcome by dose modification of everolimus. In contrast, interstitial pneumonia was the most frequent AE that caused discontinuation of everolimus even in patients with dose modification as well as in those without dose modification, suggesting that interstitial pneumonia may be eventually difficult to avert by dose modification.
Of course, this was a small-scale retrospective study. It is not appropriate to directly compare our results with those of the RECORD-1 trial because patient characteristics were not balanced between these two studies. However, all data used in the present study were obtained as a result of the strict postmarketing surveillance required by the regulatory authorities, and the results can reflect real-world clinical practice in Japan.
In conclusion, there may be some ethnic differences in the AE profile of everolimus. The timing of onset may vary according to the type of AE. In particular, interstitial pneumonia should be observed for after 1 month of treatment because of its later onset. Dose modification of everolimus might be associated with longer treatment duration in patients with advanced RCC; however, we should not posit it because the current study was retrospective and various factors other than dose modification could have significant influence on the TTF of everolimus. 
